id	author	title	date	pages	extension	mime	words	sentences	flesch	summary	cache	txt
cord-263123-5y8cc5eb	Bian, Jingwei	Anti-RAS drugs and SARS-CoV-2 infection	2020-04-28		.txt	text/plain	770	56	56	authors: Bian, Jingwei; Zhao, Rongsheng; Zhai, Suodi; Li, Zijian In addition, ACE2 is well-known as a counter-regulator of the renin-angiotensin system (RAS) and plays a key role in cardiovascular disease, especially Here, we present a completely different perspective on the relationship between SARS-CoV-2 infection and ACEI/ARB drugs. Firstly, there is no sufficient evidence to support that ACEIs and ARBs can upregulate the protein expression level of ACE2. Therefore, there is no adequate evidence to support that ACEIs/ARBs increase the risk of the SARS-CoV-2 infection by up-regulating ACE2 protein level. In addition, liver/lymph node-specific and dendritic In summary, there is currently no clear evidence indicating that anti-RAS drugs (ACEIs and ARBs) increase the risk of SARS-CoV-2 infection, as well as target organ injury. There is still no need to recommend the discontinuation of ACEIs/ARBs for hypertensive patients with or at high risk of SARS-CoV-2 infection, or the change to other antihypertensive drugs. Hypothesis: angiotensin-converting enzyme inhibitors and angiotensin receptor blockers may increase the risk of severe COVID-19	./cache/cord-263123-5y8cc5eb.txt	./txt/cord-263123-5y8cc5eb.txt